MTL CEBPA

Drug Profile

MTL CEBPA

Alternative Names: MTL-CEBPA

Latest Information Update: 21 Nov 2016

Price : $50

At a glance

  • Originator MiNA Therapeutics; University of California at San Francisco; University of Texas Southwestern Medical Center
  • Developer MiNA Therapeutics
  • Class Antineoplastics; Oligonucleotides; RNA
  • Mechanism of Action RNA stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Liver cancer

Most Recent Events

  • 14 Nov 2016 Updated pharmacodynamics data from preclinical study in Pancreatic cancer released by MiNA Therapeutics
  • 01 Feb 2016 Phase-I clinical trials in Liver cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom (IV) (NCT02716012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top